



LKT Laboratories, Inc.

LBH-589

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information

Product ID L0528

CAS No. 404950-80-7

Chemical Name

Synonym LBH589, Panobinostat

Formula $C_{21}H_{23}N_3O_2$

Formula Wt. 349.43

Melting Point


Purity $\geq 98\%$

Solubility DMSO 69 mg/mL (197.46 mM)
Water Insoluble
Ethanol Insoluble

Store Temp $-20^{\circ}C$

Ship Temp Ambient

Description LBH-589 (Panobinostat) is a hydroxamic acid inhibitor of class I (1, 2, 3, and 11) histone deacetylases (HDACs) that is clinically used to treat multiple myeloma and is currently in clinical trials as a potential treatment for other cancers. This compound displays anticancer chemotherapeutic and anti-metastatic activities. LBH-589 reverses the epithelial-to-mesenchymal transition (EMT), inhibits cell proliferation, invasion, and migration, and decreases tumor growth in animal models of breast cancer. In hepatocellular carcinoma cells, LBH-589 inhibits oncogenic miRNA expression and upregulates expression of APAF1 and Beclin-1.



Bulk quantities available upon request

Product ID	Size
L0528	5 mg
L0528	25 mg
L0528	50 mg

References Andreu-Vieyra CV, Berenson JR. The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma. *Ther Adv Hematol*. 2014 Dec;5(6):197-210. PMID: 25469210.

Rhodes LV, Tate CR, Segar HC, et al. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. *Breast Cancer Res Treat*. 2014 Jun;145(3):593-604. PMID: 24810497.

Henrici A, Montalbano R, Neureiter D, et al. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines. *Mol Carcinog*. 2013 Dec 23. [Epub ahead of print]. PMID: 24375802.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.